Hospitals | May 15, 2022
KIMS Hospitals sign MoU with Dr Raj Nagarkar to set up a hospital at Nashik
The new hospital is expected to open by March'24
The new hospital is expected to open by March'24
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
Revolutionary ovarian cancer rapid test available Q4 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
The company also raised Rs 270 crore investment from Temasek in 2019
Subscribe To Our Newsletter & Stay Updated
